[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504019":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":11,"studyPopulation":29,"armGroups":30,"interventions":11,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":36,"collaborators":11,"id":38,"slug":11,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":11,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":11,"enrollmentInfo":45,"targetDuration":11,"studyType":48,"phases":11,"briefSummary":49,"conditions":50,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Target PharmaSolutions, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"To characterize the natural history of disease in patients with autoimmune disease of various etiologies.",null,"15 Years",{"measure":14,"description":11,"timeFrame":15},"To assess safety and effectiveness of autoimmune disease treatments and treatments for complications of any related conditions","20 Years",[17,20,23],{"measure":18,"description":19,"timeFrame":12},"To evaluate provider management practices in the treatment of patients with autoimmune diseases","Health care provider type, clinic setting, reason for initiating\u002Fnot initiating\u002Fadjusting dosing of treatments, reason for discontinuing\u002Fswitching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and\u002For through linked data. Disease-specific quality measures will be selected and evaluated.",{"measure":21,"description":22,"timeFrame":12},"To evaluate longitudinal and patient reported outcomes in patients with autoimmune diseases","Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health. These measures can help clinicians better understand how the disease state and\u002For various treatments affect what patients are able to do and the symptoms they experience beyond what is typically derived and reported in the EHR as part of traditional clinical evaluations. The information can also be used to help patients make informed decisions about their healthcare and treatment options.",{"measure":24,"description":25,"timeFrame":12},"To select and evaluate quality of care measures for patients with autoimmune diseases","1. Identify and select best practices in care of patients with autoimmune diseases\n2. Develop a technology infrastructure to evaluate quality measures to support clinicians.",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":27,"timePerspective":28,"maskingInfo":11},"COHORT","OTHER","The study will include adults who are being managed for autoimmune disease",[31,34],{"label":32,"type":11,"description":33,"interventionNames":11},"Disease Cohort","Observational",{"label":35,"type":11,"description":33,"interventionNames":11},"Engaged Cohort",{"type":37,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100504019",false,"NCT05842824","An Observational Study of Patients With Autoimmune Disease","Disease Cohort\n\nInclusion Criteria:\n\n\\- Adult patients at the time of enrollment with a diagnosis autoimmune disease by select ICD-10 codes in the EHR interface\n\nExclusion Criteria:\n\n* Death\n* Manual removal (sponsor or site request)\n* No EHR interface encounter \\> 3 years\n\nEngaged Cohort\n\nInclusion Criteria:\n\n* Adult patients diagnosed and managed for these conditions invited to participate\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patient expressed desire to withdraw consent to complete PROs\n* Failure to complete PROs within 24 weeks of initial invitation\n* Greater than 24 months lapse of survey completion after baseline surveys completed\n* Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort","ALL","18 Years",{"count":46,"type":47},500000,"ESTIMATED","OBSERVATIONAL","TARGET-AUTOIMMUNE is an observational research study to conduct a comprehensive review of outcomes for patients with autoimmune and related diseases. .",[51],"Autoimmune Diseases","NOT_YET_RECRUITING","2024-11-18",{"date":55,"type":56},"2024-11-20","ACTUAL",{"date":58,"type":47},"2025-03-31",{"date":60,"type":47},"2038-12-31",{"name":5,"class":6}]